Is it impossible to stop taking Enasidenib once you take it?

Enasidenib As a targeted inhibitor that acts on IDH2 mutations, its core mechanism is to reduce the level of 2-HG in leukemia cells by intervening in abnormal metabolic pathways, thereby restoring the maturation process of primitive cells with blocked differentiation. In practical applications, this drug is not a "chemotherapy kill" in the traditional sense, but a treatment method that restores differentiation function by regulating the cell metabolic environment. Because of this unique mechanism, ensidipine needs to be taken continuously and regularly to maintain a stable inhibitory effect in the body and avoid disease recurrence or decrease in efficacy due to interruption.

Whether"You cannot stop taking the medicine once you start taking it" is actually not absolute. Generally speaking, as long as the disease is under control, patients need to take medication regularly for a long time, and the risk of drug discontinuation is high, especially in diseases with high relapse rates such as acute myeloid leukemia (AML). If you stop taking the medicine without authorization, it may cause abnormal cells to proliferate again, thus affecting the therapeutic effect. But this does not mean that all patients cannot stop taking the drug for life. Whether to discontinue the drug or not needs to be decided based on the disease remission, tolerance of adverse reactions, and the doctor's comprehensive judgment. For example, if serious adverse reactions occur during treatment, the doctor may ask to reduce the dosage or suspend the treatment, and then resume medication after the symptoms are relieved. On the other hand, if new treatment alternatives become available in the future, doctors may also adjust the medication strategy according to the situation.

Patients must maintain regular follow-up visits while taking the drug, and undergo regular hematological and molecular testing to evaluate efficacy and tolerance. Any decision to discontinue or adjust dosage should be evaluated by a specialist hematologist and not at the discretion of the patient. Overall, ensidipine treatment emphasizes long-term stability, and its efficacy is highly related to the persistence of medication. Therefore, patients should establish scientific medication awareness and conduct full management under guidance.

Reference materials:https://www.idhifa.com/